News

Filter

Current filters:

Novartis

1 to 9 of 3657 results

Novartis, Boehringer and Celgene present new psoriasis data at AAD meeting

Novartis, Boehringer and Celgene present new psoriasis data at AAD meeting

23-03-2015

Novartis, Boehringer Ingelheim and Celgene have presented positive data on their dermatology products…

Boehringer IngelheimCelgene CorpCosentyxDermatologicalsNovartisOtezlaPharmaceuticalResearchStelara

Most promising drugs of 2015 identified in new report

23-03-2015

Annual forecast finds significant increase in the number of blockbuster drug set to enter this year’s…

Bristol-Myers SquibbGlobalLCZ-696Markets & MarketingNovartisOpdivoPharmaceuticalPraluentRegeneron PharmaceuticalsSanofi

Amgen knocked back as US district court will not block Sandoz's Neupogen biosimilar

Amgen knocked back as US district court will not block Sandoz's Neupogen biosimilar

20-03-2015

The US district court has rejected Amgen’s request for a preliminary injunction to block Sandoz’s…

AmgenAntibiotics and Infectious diseasesBiosimilarsFilgrastimLegalNeupogenNovartisOncologySandozUSAZarxio

EC approves new indication for Novartis’ Jakavi

EC approves new indication for Novartis’ Jakavi

17-03-2015

The European Commission has approved Swiss pharma giant Novartis’ Jakavi (ruxolitinib) for the treatment…

BiotechnologyEuropeIncyte CorpJakafiJakaviNovartisOncologyRegulation

Highlights of EMA’s PRAC March meetings

13-03-2015

The European Medicines Agency has released highlights of the March 9-12 meeting of its Pharmacovigilance…

Anti-Arthritics/RheumaticscodeineEuropeNeurologicalNovartisPharmaceuticalRegulationzoledronic acid

Second $50M milestone for Ophthotech under Fovista deal with Novartis

11-03-2015

US biotech firm Ophthotech says it has achieved a second $50 million enrollment milestone from Swiss…

BiotechnologyFinancialFovistaNovartisOphthalmicsOphthotechResearch

NICE gives go ahead for Xolair to treat potentially disabling skin condition

NICE gives go ahead for Xolair to treat potentially disabling skin condition

11-03-2015

The medicines cost watchdog the National Institute of Health and Care Excellence (NICE) has recommended…

DermatologicalsNovartisPharmaceuticalPricingRegulationUKXolair

Germany’s IQWiG finds no added benefit for Novartis’ Galvus

Germany’s IQWiG finds no added benefit for Novartis’ Galvus

09-03-2015

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined in a new dossier…

DiabetesGalvusGermanyNovartisPharmaceuticalPricingRegulation

1 to 9 of 3657 results

Back to top